Akero's Efruxifermin Shows Cirrhosis Reversal In MASH Patients, Stock Soars In Pre-Market
In the trial, dubbed SYMMETRY, Efruxifermin demonstrated statistically significant cirrhosis reversal in patients with biopsy-confirmed compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis or MASH.
Bank of America upgraded Akero Therapeutics (NASDAQ:AKRO) on Thursday, citing what it called “game-changing” data the company ...
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
Akero Therapeutics (AKRO) released preliminary topline week 96 results from SYMMETRY, a Phase 2b study evaluating the efficacy and safety of ...
The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically ...
Akero Therapeutics shares doubled to $55.64 in premarket trading after the company said it saw positive preliminary topline results from its Phase 2b study evaluating the efficacy and safety of its ...
After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
Analyst David Lebowitz of Citi maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a price target of $65.00.Invest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback